UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL 3235-0287 OMB Number: Estimated average burden hours per response..

longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses))											
Name and Address of Arch Venture Fund V	2. Issuer Name and Ticker or Trading Symbol Syros Pharmaceuticals, Inc. [SYRS]					5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X 10% Owner						
(Last) (First) (Middle) 8755 WEST HIGGINS ROAD, SUITE 1025			3. Date of Earliest Transaction (Month/Day/Year) 07/06/2016						ther (specify belo	ow)		
(Street) CHICAGO, IL 60631			4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) Form filed by One Reporting Person X_Form filed by More than One Reporting Person			
(City)	Table I - Non-Derivative Securities Acqui						red, Disposed of, or Beneficially Owned					
1.Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year)		(Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	Form:	7. Nature of Indirect Beneficial	
			(Month/Day/Year)	Code	v	Amount	(A) or (D)	Price	(Instr. 3 and 4)	Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)	
Common Stock		07/06/2016		С		266,666	A	(1)	479,999	D (5)		
Common Stock		07/06/2016		С		1,333,333	A	<u>(2)</u>	1,813,332	D (5)		
Common Stock		07/06/2016		С		2,000,000	A	<u>(3)</u>	3,813,332	D (5)		
Common Stock		07/06/2016		С		423,805	A	<u>(4)</u>	4,237,137	D (5)		
Common Stock		07/06/2016		P		400,000	A	\$ 12.5	4,637,137	D (5)		
Reminder: Report on a se	eparate line for eac	ch class of securities	beneficially owned			•	espond	l to th	e collection of information conta	ined SEC	1474 (9-02)	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

in this form are not required to respond unless the form displays a currently valid OMB control number.

	(e.g., puts, cans, warrants,							options, convertible securities)							
	Conversion		Execution Date, if	4. Transact	tion	Der	ivative	6. Date Exercisable and Expiration Date (Month/Day/Year)						Ownership	11. Nature of Indirect Beneficial
(Instr. 3)	Price of Derivative Security	(Month/Day/Year)	any (Month/Day/Year))	Acc Dis	quired (A) or posed of (D) ttr. 3, 4, and		// Year)	,		(Instr. 5)	Beneficially Owned Following Reported	Derivative Security: Direct (D) or Indirect	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date		Amount or Number of Shares		Transaction(s) (Instr. 4)	(I) (Instr. 4)	
Series A- 1 Preferred Stock	(1)	07/06/2016		С			1,000,000	<u>(1)</u>	<u>(1)</u>	Common Stock	266,666	\$ 0	0	D (5)	
Series A- 2 Preferred Stock	(2)	07/06/2016		С			5,000,000	<u>(2)</u>	(2)	Common Stock	1,333,333	\$ 0	0	D (5)	
Series A- 3 Preferred Stock	(3)	07/06/2016		С			7,500,000	(3)	(3)	Common Stock	2,000,000	\$ 0	0	D (5)	
Series B Preferred Stock	<u>(4)</u>	07/06/2016		С			1,589,269	<u>(4)</u>	<u>(4)</u>	Common Stock	423,805	\$ 0	0	D (5)	

Reporting Owners

Donastina Oroman Nama / Adduses	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Arch Venture Fund VII LP 8755 WEST HIGGINS ROAD, SUITE 1025 CHICAGO, IL 60631		X				
ARCH Venture Partners VII, L.P. 8755 WEST HIGGINS ROAD, SUITE 1025 CHICAGO, IL 60631		X				
ARCH Venture Partners VII, LLC 8755 WEST HIGGINS ROAD, SUITE 1025 CHICAGO, IL 60631		X				

CRANDELL KEITH 8755 WEST HIGGINS ROAD, SUITE 1025 CHICAGO, IL 60631	X	
BYBEE CLINTON 8755 WEST HIGGINS ROAD, SUITE 1025 CHICAGO, IL 60631	X	

Signatures

ARCH Venture Fund VII, L.P. By: ARCH Venture Partners VII, L.P. By: /s/Mark McDonnell, as Attorney-in-Fact for Keith Crandell, the Mgng Dir of ARCH VII LLC, the GP of ARCH Partners VII, the GP of ARCH Fund VII Name: Mark McDonnell Title: Attorney-in fact	07/06/2016					
"Signature of Reporting Person						
ARCH Venture Partners VII, L.P. By: ARCH Venture Partners VII, LLC By: /s/ Mark McDonnell as Attorney-in-Fact for Keith Crandell, the Managing Director of ARCH VII LLC, the general partner of ARCH Partners VII Name: Mark McDonnell Title: Attorney-in fact	07/06/2016					
-*Signature of Reporting Person	Date					
ARCH Venture Partners VII, LLC By: /s/ Mark McDonnell as Attorney-in-Fact for Keith Crandell, the Managing Director of ARCH VII LLC Name: Mark McDonnell Title: Attorney-in fact	07/06/2016					
**Signature of Reporting Person	Date					
/s/ Mark McDonnell, as Attorney-in-Fact for Keith Crandell Keith Crandell	07/06/2016					
**Signature of Reporting Person	Date					
/s/ Mark McDonnell, as Attorney-in-Fact for Clinton Bybee	07/06/2016					
Signature of Reporting Person	Date					

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The Series A-1 Preferred Stock converted into Common Stock on a 3.75-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-1 Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
- The Series A-2 Preferred Stock converted into Common Stock on a 3.75-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-2 Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
- (3) The Series A-3 Preferred Stock converted into Common Stock on a 3.75-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-3 Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
- (4) The Series B Preferred Stock converted into Common Stock on a 3.75-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

 These shares are owned directly by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"). The sole general partner of ARCH VII LLC, Robert T. Nelsen,
- (5) Keith Crandell and Clinton Bybee, are deemed to have voting and dispositive power over the shares and may be deemed to beneficially own certain shares held by ARCH Fund VII. Each Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of such securities for Section 16 or any other purpose.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.